Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, double blinded, active and placebo controlled randomized
clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615;
RN316) compared to placebo in subjects who are statin intolerant.